ERBB2 and neoplasm: We then subdivided the tumors into two groups according to the miR-129-5p median expression and analyzed the relationship between miR-129-5p expression and clinicopathologic features known to affect patient outcome, including patient age, menopausal status, tumor size, clinical stage, histological grade, lymph node status, and ER/PR/Her2 status.